Q3 EPS Estimate for CRISPR Therapeutics Lifted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.58) for the quarter, up from their prior forecast of ($1.62). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($5.38) EPS and FY2026 earnings at ($5.38) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. During the same period last year, the business earned ($1.49) EPS. CRISPR Therapeutics’s quarterly revenue was up 72.5% compared to the same quarter last year.

CRSP has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Needham & Company LLC restated a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Friday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Finally, Chardan Capital restated a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $72.59.

CRISPR Therapeutics Stock Up 1.1%

CRSP stock opened at $69.15 on Friday. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $78.48. The stock’s 50 day moving average is $60.44 and its 200-day moving average is $50.00. The firm has a market capitalization of $6.29 billion, a PE ratio of -12.73 and a beta of 1.84.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 4,242 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total value of $282,517.20. Following the sale, the chief executive officer owned 205,096 shares in the company, valued at $13,659,393.60. This trade represents a 2.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in the company. Perigon Wealth Management LLC raised its stake in shares of CRISPR Therapeutics by 2.1% in the third quarter. Perigon Wealth Management LLC now owns 18,692 shares of the company’s stock valued at $1,211,000 after buying an additional 380 shares during the period. Sowell Financial Services LLC bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at $231,000. Thompson Investment Management Inc. bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at $33,000. Apollon Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at $446,000. Finally, Darwin Wealth Management LLC raised its stake in shares of CRISPR Therapeutics by 99.8% in the third quarter. Darwin Wealth Management LLC now owns 925 shares of the company’s stock valued at $60,000 after buying an additional 462 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.